UNSPSC 51111736: Cetuximab

This classification denotes a monoclonal antibody with the molecular formula C6484H10042N1732O2023S36, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PQX0D8J21J, more generally known as cetuximab. European Medicines Agency schedules cetuximab in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01178MIG. The term CETUXIMAB is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 14, no. 3, 2000, list 44. Most nations schedule cetuximab under HS 30021091 and SITC 54163.

As of Q4 2014, CETUXIMAB remains the US FDA Preferred Term for this commodity. Cetuximab bears US NLM identifiers UMLS ID C0995188 and NCI Concept Code C1723. SMILES: CC(=O)NC1C(C(C(OC1N)CO)O)O.

UNSPSC 51111736 Cetuximab is a Commodity code that nominally designates a specific monoclonal antibody drug, but recent state and local procurement activity under this code bears no relation to that scope. The opportunities posted against this code — naloxone procurement for Seminole County, medical and first aid supplies for Tampa Fire Department, generic multi-source pharmaceuticals and OTC products through the Minnesota Multistate Cooperative Purchasing Alliance, and a pharmacy benefit program market-intelligence RFI from the Texas Health and Human Services Commission — involve emergency medications, general first aid supplies, and broad-spectrum pharmaceutical and OTC products, not cetuximab or oncology treatments. This mismatch suggests the code is either miscategorized in state and local procurement systems or being used as a catch-all for pharmaceutical and related supply solicitations that do not fit narrower commodity classifications. Issuing bodies include county health departments (Seminole County, Florida), municipal fire departments (City of Tampa), state health agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Department of Administration administering MMCAP), reflecting the broad and fragmented jurisdiction mix typical of pharmaceutical procurement across state and local government.

Geographic activity centers on Florida and the multistate MMCAP region (Minnesota and Oregon), with additional recent movement from Texas. Representative opportunities include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, due July 26, 2023; the City of Tampa's sealed-bid procurement (26P00145) for 169 line items of medical and first aid supplies for the Fire Department Rescue Division with an estimated contract value of $700,000, sheltered for certified Small Local Business Enterprises with a 5 percent bid discount, and a response deadline of March 13, 2026; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson), with proposals due March 26, 2026. The Texas RFI solicited vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, posted April 3, 2026, as an exploratory information-gathering mechanism preceding formal procurement. The code shows recent activity but misalignment with its nominal scope warrants verification of the underlying commodity classification before committing pursuit resources.